@article{ref1,
title="Pegylated interferons",
journal="Journal of Drug Evaluation",
year="2004",
author="D'Souza, R. and Foster, G.R.",
volume="2",
number="4",
pages="113-127",
abstract="PEG-interferons have improved pharmacokinetics by allowing a once-weekly dosing regimen that provides constant and sustained therapeutic plasma concentrations, and, as a result, a constant and sustained antiviral pressure over the entire dosing period. This in turn, leads to PEG-IFN having significantly improved response rates over conventional IFN in patients suffering from chronic hepatitis B and C, and it is likely that the improved response rates with these new compounds will lead to more patients eradicating these life threatening viruses. © 2004 Parthonon Publishing.<p /><p>Language: en</p>",
language="en",
issn="1479-1137",
doi="10.1080/14791130400023643",
url="http://dx.doi.org/10.1080/14791130400023643"
}